Trials / Terminated
TerminatedNCT02658916
Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003
A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 41 Years – 86 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of multiple intravenous (IV) infusions of BIIB092 in participants with Progressive Supranuclear Palsy (PSP). The study will also assess the pharmacodynamic (PD) effects of BIIB092 on cerebrospinal fluid (CSF) N-terminal tau, pharmacokinetics (PK), and immunogenicity of BIIB092 in participants with PSP.
Detailed description
This study, previously posted by Bristol-Myers Squibb, has transitioned to Biogen under a licensing agreement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIIB092 | Same dose as corresponding CN002003 study panel. |
Timeline
- Start date
- 2016-02-22
- Primary completion
- 2020-03-31
- Completion
- 2020-03-31
- First posted
- 2016-01-20
- Last updated
- 2020-05-18
Locations
13 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02658916. Inclusion in this directory is not an endorsement.